High Tower Advisors, LLC Lian Bio Transaction History

High Tower Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.79 - $2.85 $3,580 - $5,700	-2,000 Reduced 5.8%	32,500 $74,000
Q1 2023 May 11, 2023	SELL	$1.57 - $2.66 $21,980 - $37,240	-14,000 Reduced 28.87%	34,500 $67,000
Q4 2022 Feb 08, 2023	BUY	$1.14 - $2.11 $10,829 - $20,045	9,500 Added 24.36%	48,500 $79,000
Q3 2022 Nov 09, 2022	BUY	$1.87 - $3.0 $37,587 - $60,300	20,100 Added 106.35%	39,000 $78,000
Q2 2022 Aug 10, 2022	BUY	$2.15 - $6.01 $40,635 - $113,589	18,900 New	18,900 $40,000

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $32.5M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.